Jeff E. Knight, Chief Development & Operating Officer at Crinetics Pharmaceuticals (NASDAQ: CRNX), completed a notable set of transactions on April 8, 2026. Knight sold 85,163 shares of the company's common stock at an average price of $40.10 per share, producing proceeds of $3,415,036. The executed sale fell within a trading range of $40.00 to $40.34 on that date.
Concurrently, Knight exercised stock options to acquire 78,434 shares of Crinetics common stock. Those option exercises carried exercise prices between $19.64 and $23.98 and resulted in a total outlay of $1,758,818.
The publicly disclosed sales were carried out automatically under a pre-arranged Rule 10b5-1 trading plan that Knight adopted on December 12, 2025. After these transactions were completed, Knight directly held 105,289 shares of Crinetics Pharmaceuticals.
These insider moves come as the company released its fourth-quarter results for 2025, which beat consensus expectations. Crinetics reported an earnings per share (EPS) of -$1.29 for the quarter, outpacing the forecasted -$1.34. Revenue for Q4 was $6.1 million, also above the anticipated $4 million.
On the regulatory front, Crinetics has submitted a Marketing Authorization Application to Brazil’s National Health Surveillance Agency for Palsonify, an oral treatment intended for acromegaly. The submission is supported by data from 18 clinical trials, including two successful Phase 3 studies.
Separately, Crinetics announced that Knight will step down from his role as Chief Development and Operating Officer effective April 10, 2026. The company stated that his resignation is not the result of any disagreements with management or the board.
Market analysis and analyst activity provide additional context. InvestingPro's evaluation indicates that Crinetics' stock currently appears overvalued relative to its Fair Value estimate; the platform notes the company is valued at approximately $4.12 billion and offers supplementary ProTips and a comprehensive Pro Research Report on the shares.
Meanwhile, Citizens reduced its price target for Crinetics from $105 to $96 but retained a Market Outperform rating. That adjustment followed early launch metrics for Palsonify, with the bank citing physician expectations for significant uptake in the U.S. market as part of the rationale behind its revised estimate.
The sequence of insider sales, option exercises, regulatory filing activity, quarterly results and analyst re-rating provides multiple data points for investors monitoring Crinetics. Each item is factual and disclosed by the company, and all timing and amounts above reflect the company filings and published analyst commentary.